A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer

Charlie Gourley; James Cassidy; Chris Edwards; Leslie Samuel; Donald Bisset; Gabriella Camboni; Anne Young; Dorothy Boyle; Duncan Jodrell

doi:10.1007/s00280-003-0721-x

A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer

Charlie Gourley, James Cassidy, Chris Edwards, Leslie Samuel, Donald Bisset, Gabriella Camboni, Anne Young, Dorothy Boyle, Duncan Jodrell

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

BBR 3464 is a novel trinuclear platinum anticancer agent with a broad spectrum of preclinical antitumour activity. A phase I, open-label dose-escalating study was performed to determine the maximum tolerated dose (MTD) of BBR 3464 administered in combination with protracted venous infusional (PVI) 5-fluorouracil (5-FU) for up to six courses in patients with locally advanced and/or metastatic cancer.

Original language	English
Pages (from-to)	95-101
Number of pages	7
Journal	Cancer chemotherapy and pharmacology
Volume	53
Issue number	2
DOIs	https://doi.org/10.1007/s00280-003-0721-x
Publication status	Published - Feb 2004

Keywords / Materials (for Non-textual outputs)

Adult
Aged
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Diarrhea
Fatigue
Female
Fluorouracil
Hematologic Diseases
Humans
Male
Maximum Tolerated Dose
Middle Aged
Nausea
Neoplasms
Organoplatinum Compounds

Access to Document

10.1007/s00280-003-0721-x

Cite this

Gourley, C., Cassidy, J., Edwards, C., Samuel, L., Bisset, D., Camboni, G., Young, A., Boyle, D., & Jodrell, D. (2004). A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. Cancer chemotherapy and pharmacology, 53(2), 95-101. https://doi.org/10.1007/s00280-003-0721-x

@article{22c67f8b1acb4935abfb71450d52d860,

title = "A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer",

abstract = "BBR 3464 is a novel trinuclear platinum anticancer agent with a broad spectrum of preclinical antitumour activity. A phase I, open-label dose-escalating study was performed to determine the maximum tolerated dose (MTD) of BBR 3464 administered in combination with protracted venous infusional (PVI) 5-fluorouracil (5-FU) for up to six courses in patients with locally advanced and/or metastatic cancer.",

keywords = "Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Diarrhea, Fatigue, Female, Fluorouracil, Hematologic Diseases, Humans, Male, Maximum Tolerated Dose, Middle Aged, Nausea, Neoplasms, Organoplatinum Compounds",

author = "Charlie Gourley and James Cassidy and Chris Edwards and Leslie Samuel and Donald Bisset and Gabriella Camboni and Anne Young and Dorothy Boyle and Duncan Jodrell",

year = "2004",

month = feb,

doi = "10.1007/s00280-003-0721-x",

language = "English",

volume = "53",

pages = "95--101",

journal = "Cancer chemotherapy and pharmacology",

issn = "0344-5704",

publisher = "Springer",

number = "2",

}

Gourley, C, Cassidy, J, Edwards, C, Samuel, L, Bisset, D, Camboni, G, Young, A, Boyle, D & Jodrell, D 2004, 'A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer', Cancer chemotherapy and pharmacology, vol. 53, no. 2, pp. 95-101. https://doi.org/10.1007/s00280-003-0721-x

TY - JOUR

T1 - A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer

AU - Gourley, Charlie

AU - Cassidy, James

AU - Edwards, Chris

AU - Samuel, Leslie

AU - Bisset, Donald

AU - Camboni, Gabriella

AU - Young, Anne

AU - Boyle, Dorothy

AU - Jodrell, Duncan

PY - 2004/2

Y1 - 2004/2

N2 - BBR 3464 is a novel trinuclear platinum anticancer agent with a broad spectrum of preclinical antitumour activity. A phase I, open-label dose-escalating study was performed to determine the maximum tolerated dose (MTD) of BBR 3464 administered in combination with protracted venous infusional (PVI) 5-fluorouracil (5-FU) for up to six courses in patients with locally advanced and/or metastatic cancer.

AB - BBR 3464 is a novel trinuclear platinum anticancer agent with a broad spectrum of preclinical antitumour activity. A phase I, open-label dose-escalating study was performed to determine the maximum tolerated dose (MTD) of BBR 3464 administered in combination with protracted venous infusional (PVI) 5-fluorouracil (5-FU) for up to six courses in patients with locally advanced and/or metastatic cancer.

KW - Adult

KW - Aged

KW - Antineoplastic Agents

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Diarrhea

KW - Fatigue

KW - Female

KW - Fluorouracil

KW - Hematologic Diseases

KW - Humans

KW - Male

KW - Maximum Tolerated Dose

KW - Middle Aged

KW - Nausea

KW - Neoplasms

KW - Organoplatinum Compounds

U2 - 10.1007/s00280-003-0721-x

DO - 10.1007/s00280-003-0721-x

M3 - Article

C2 - 14605864

SN - 0344-5704

VL - 53

SP - 95

EP - 101

JO - Cancer chemotherapy and pharmacology

JF - Cancer chemotherapy and pharmacology

IS - 2

ER -

A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this